Business Context and Reporting Period
The filing is Gemphire Therapeutics Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2017. The request metadata identifies “Metavia Inc.”, but the filing identifies the registrant as Gemphire Therapeutics Inc.
Gemphire was a clinical-stage biopharmaceutical company developing gemcabene, an oral therapy for dyslipidemia and NAFLD/NASH. The company had no approved products and generated no revenue.
Key Financial Metrics
| Metric | Q1 2017 | Q1 2016 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| General and administrative expense | $2.2 million | $1.1 million | +$1.2 million |
| Research and development expense | $5.3 million | $1.2 million | +$4.1 million |
| Total operating expenses | $7.5 million | $2.2 million | +$5.3 million |
| Net loss | $7.5 million | $2.1 million | +$5.4 million loss |
| Basic and diluted loss per share | $0.79 loss | $0.65 loss | Loss per share increased |
| Net cash used in operating activities | $6.2 million | $2.1 million | +$4.2 million use |
| Net cash provided by financing activities | $11.5 million | $0.1 million | +$11.4 million |
Cash and cash equivalents were $29.3 million at March 31, 2017, compared with $24.0 million at December 31, 2016. Total assets were $29.8 million and total liabilities were $4.5 million. The company reported stockholders’ equity of $25.3 million and an accumulated deficit of $34.6 million.
The company had no debt outstanding at March 31, 2017. Its former Interim Notes converted into common stock before the August 2016 IPO. No income tax provision or benefit was recorded because operating losses were fully offset by a valuation allowance on deferred tax assets.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased 349%, primarily because three Phase 2b clinical trials were active in Q1 2017 versus no active clinical studies in the prior-year period.
- General and administrative expense increased 112%, driven by higher personnel, share-based compensation, professional-service and public-company infrastructure costs.
- Total share-based compensation increased to $836,000 from $123,000.
- Net cash used in operations increased to $6.2 million from $2.1 million.
- On March 15, 2017, the company raised approximately $12.5 million in gross proceeds, or approximately $11.3 million net, through a private placement of 1,324,256 units.
- Each private-placement unit included one common share and a five-year warrant to purchase 0.75 shares at an exercise price of $10.40. The transaction generated warrants exercisable for 993,204 shares, creating potential dilution.
- Common shares outstanding increased to 10,596,838 at March 31, 2017 from 9,270,255 at December 31, 2016.
Guidance, Outlook, Risks and Unusual Items
Management expected top-line data from the COBALT-1 and ROYAL-1 trials by the end of the second and third quarters of 2017, respectively, and from INDIGO-1 by the first quarter of 2018. Management also planned to initiate a Phase 2 NASH trial in the second half of 2017, with top-line data expected in the second half of 2018, followed by potential End-of-Phase-2 discussions with the FDA and other health authorities.
The company expected expenses to increase substantially as clinical development, regulatory activities, manufacturing planning, intellectual-property protection, staffing and public-company costs expanded. Management stated that it would need additional capital to fund development and operations and had no committed external source of funds.
- Gemcabene remained subject to clinical, regulatory, manufacturing and commercialization risks, and the company could not assure eventual approval, revenue generation or profitability.
- Cash requirements could exceed current estimates because clinical-trial timing, enrollment, costs, safety monitoring and regulatory requirements were uncertain.
- Future equity or convertible-debt financings could dilute existing holders; collaborations could require relinquishing valuable rights.
- The Pfizer license included potential milestone payments of up to $37 million and tiered royalties on future sales. No milestone or royalty payments had been triggered as of March 31, 2017.
- Pfizer could revoke the license if the company was unable to adequately commercialize gemcabene by April 2021, subject to the agreement’s terms.
- Share-based compensation included $11.2 million of unrecognized stock-option expense at March 31, 2017, expected to be recognized over a weighted-average period of 3.1 years.
- The resale registration statement covering the private-placement securities became effective on April 20, 2017.
- Management reported effective disclosure controls as of March 31, 2017 and no material changes in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Confirm the issuer identity: the provided filing is for Gemphire Therapeutics Inc., not Metavia Inc.
- Review the timing and results of the COBALT-1, ROYAL-1 and INDIGO-1 trials and the planned NASH study.
- Assess cash runway using the $29.3 million cash balance, $6.2 million quarterly operating cash burn and expected escalation in clinical spending.
- Evaluate dilution from 10.6 million common shares outstanding, 993,204 private-placement warrants and 2.36 million anti-dilutive stock options.
- Review the terms and registration status of the private-placement securities and any related-party participation.
- Monitor the Pfizer license, potential milestone obligations, commercialization requirements and the April 2021 termination risk.
- Read the company’s 2016 Form 10-K risk factors referenced by this filing, including risks related to clinical development, regulatory approval, financing and future profitability.